Amgen Inc. (AMGN) Earnings Call Transcripts
Amgen Inc.'s Latest Earnings Call - September 15, 2026
In the third quarter of fiscal year 2026, Amgen Inc. reported total revenues of over $10 billion, reflecting a 10% year-on-year increase, driven by strong performance across its six growth drivers, which collectively grew 26%. The company achieved strong earnings performance while increasing investments in innovation. Management highlighted significant opportunities ahead, particularly with the promising Phase III results for IMDELLTRA and ongoing advancements in their biosimilar portfolio. Guidance for the upcoming quarters remains optimistic, with a focus on durable growth and continued pipeline development.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $10B (beat) |
| Growth Drivers Revenue Growth | 26% (positive) |
| Earnings Performance | null (null) |
| Number of Products with Double-Digit Growth | 22 (positive) |
| Biosimilar Regulatory Submissions | 2 (positive) |
| Phase III Trials for IMDELLTRA | 2 (positive) |
Guidance from management
Management maintained a positive outlook for future growth, focusing on expanding patient access and pipeline advancements, with an emphasis on driving durable growth over the next decade.
What management said
Great. Looking forward to it. I guess the first place I want to start, I've been asking most companies this is just it seems like we're in a different place from a policy perspective versus last year. And so anything that the company is picking up coming out of D.C. as we head into midterm season that we should have on our radar screen.
Okay. And then the kind of related question is 340B, I know, has been a tailwind for a number of companies in 2Q, and there's this pilot that's going in place in January. So how should we think about that heading into 2027 as a potential tailwind to the business?
What analysts pressed on
Analysts expressed concerns regarding the potential impact of policy changes in D.C., particularly related to the 340B program and reimbursement pricing. There were also questions about the competitive landscape for cardiovascular drugs and how upcoming data from competitors might affect Amgen's pipeline assets.
Main topics on the call
- Strong Revenue Growth — Amgen's total revenues exceeded $10 billion, up 10% year-on-year, with 22 products delivering double-digit sales growth. Management noted, "Our 6 growth drivers...really delivered," indicating robust portfolio performanc...
- Pipeline Advancements — Management announced landmark Phase III results for IMDELLTRA, which showed statistically significant improvements in survival rates for small cell lung cancer patients. This was described as an "important inflection poi...
- Biosimilar Portfolio Progress — Amgen is advancing its biosimilar candidates, including ABP 234 for KEYTRUDA, which met primary and secondary endpoints in Phase III studies. The company expects regulatory submissions in the second half of the year, ind...
- Investment in Innovation — Management emphasized a commitment to funding innovation and commercial investments, stating, "Our strategy or hierarchy is very clear. It's about really number one, funding innovation." This reflects a long-term growth ...
Read the full Amgen Inc. transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Amgen Inc.
Amgen Inc. (AMGN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 135 calls on record spanning January 9, 2020 to September 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 135 Amgen Inc. earnings call transcripts on record, spanning January 9, 2020 to September 15, 2026. Based on this history, Amgen Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- AMGN
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 135
- First call
- January 9, 2020
- Most recent
- September 15, 2026
- Reporting cadence
- quarterly